Core Viewpoint - A class action lawsuit has been filed against Lineage, Inc. for alleged material misrepresentations in its IPO registration statement, which misled investors about the company's business and financial health [8]. Allegation Details - The lawsuit claims that the Registration Statement contained false information regarding Lineage's business performance and industry trends at the time of the IPO, particularly regarding the impact of the COVID-19 pandemic on cold storage demand [8]. - It is alleged that instead of experiencing growth, Lineage was facing a downturn as customers reduced inventory levels and the company struggled with occupancy rates and pricing power due to unsustainable price increases [8]. Stock Performance - Since the IPO, Lineage's stock price has dropped to approximately $40 per share, which is about half of the IPO price [8].

Core Points - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged misrepresentation regarding its New Drug Application for oxylanthanum carbonate [8] - The lawsuit covers all individuals and entities that purchased Unicycive securities between March 29, 2024, and June 27, 2025, with a deadline of October 14, 2025, to apply as lead plaintiff [8] - The complaint alleges that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements, which led to significant stock price declines following negative FDA inspections [8] Allegation Details - The lawsuit claims that Unicycive assured investors of its ability to satisfy FDA requirements but failed to disclose deficiencies identified by the FDA at a third-party manufacturing vendor [8] - Following the announcement of these deficiencies on June 10, 2025, Unicycive's stock price fell over 40% [8] - On June 30, 2025, the FDA issued a Complete Response Letter for the NDA, resulting in a further stock price decline of almost 30%, closing at $4.77 per share [8] Next Steps - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact Bragar Eagel & Squire, P.C. for more information [4] - The law firm represents both individual and institutional investors in complex litigation across various courts [5]

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its treatment ALTO-100 for Major Depressive Disorder (MDD) [7]. Allegation Details - The lawsuit claims that the Offering Documents for Alto's IPO were negligently prepared and that the company failed to disclose critical information about ALTO-100's effectiveness [7]. - Specifically, it is alleged that ALTO-100 was less effective in treating MDD than the company had indicated, leading to overstated clinical, regulatory, and commercial prospects [7]. Stock Performance Impact - Following the announcement of the Phase 2b trial results on October 22, 2024, which indicated that ALTO-100 did not meet its primary endpoint, Alto's stock price plummeted by $10.17 per share, a decrease of 69.99%, closing at $4.36 per share on October 23, 2024 [7]. Next Steps for Investors - Investors who purchased Alto securities between February 2, 2024, and October 22, 2024, are encouraged to contact the law firm for more information and to discuss their legal rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is September 19, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5]. - The firm has offices in New York, California, and South Carolina and specializes in commercial and securities litigation [5].

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug ALTO-100 during the class period from February 2, 2024, to October 22, 2024 [2][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Alto securities during the specified class period [2]. - Investors have until September 19, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. - The complaint alleges that the Offering Documents for the IPO were negligently prepared and that key information about ALTO-100's effectiveness was not disclosed [3]. Group 2: Impact on Stock Price - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in a Phase 2b trial for treating Major Depressive Disorder (MDD), leading to a significant stock price drop [4]. - Following the announcement, Alto's stock price fell by $10.17 per share, or 69.99%, closing at $4.36 per share on October 23, 2024 [4]. Group 3: Contact Information - Investors who suffered losses or have questions regarding the lawsuit can contact Bragar Eagel & Squire, P.C. for more information [5][8].

Core Viewpoint - A class action lawsuit has been filed against Replimune Group, Inc. for allegedly making false and misleading statements regarding the IGNYTE trial, which led to investor losses during the specified class period [1][3]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Replimune securities between November 22, 2024, and July 21, 2025, with a deadline of September 22, 2025, for investors to apply as lead plaintiffs [1]. - Allegations include that defendants overstated the IGNYTE trial's prospects and failed to disclose material issues, resulting in the FDA deeming the trial inadequate [3]. Investor Information - Investors who suffered losses or have questions regarding their rights are encouraged to contact the law firm for more information [4]. - The law firm emphasizes that there is no cost or obligation for investors to inquire about their claims [4]. Law Firm Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation across the United States [5].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making materially false and misleading statements regarding its business practices and partnerships, particularly concerning the promotion of illegitimate versions of the weight-loss drug Wegovy [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Hims securities between April 29, 2025, and June 23, 2025, with a deadline of August 25, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Hims engaged in deceptive practices that jeopardized patient safety and risked the termination of its collaboration with Novo Nordisk [3][4]. Group 2: Allegations Against Hims - Specific allegations include the failure to disclose that Hims was promoting illegitimate versions of Wegovy, which posed risks to patient safety [3]. - The complaint also claims that Hims misrepresented the nature of its collaboration with Novo Nordisk, suggesting that it would ensure continued access to Wegovy for Hims subscribers [4]. Group 3: Investor Communication - Investors who suffered losses or have information related to the case are encouraged to contact the law firm Bragar Eagel & Squire for further assistance [5]. - The law firm specializes in representing individual and institutional investors in complex litigation [6].

Core Points - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged misrepresentation regarding its New Drug Application for oxylanthanum carbonate [8] - The lawsuit covers all individuals and entities that purchased Unicycive securities between March 29, 2024, and June 27, 2025, with a deadline of October 14, 2025, to apply as lead plaintiff [8] - The complaint claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements, which led to significant stock price declines following negative FDA inspections [8] Allegation Details - The lawsuit alleges that Unicycive's management assured investors of the company's ability to satisfy FDA requirements, which was later revealed to be overstated [8] - On June 10, 2025, Unicycive disclosed that the FDA identified deficiencies in cGMP compliance at a third-party vendor, leading to a stock price drop of over 40% [8] - Following a Complete Response Letter from the FDA on June 30, 2025, citing the same deficiencies, Unicycive's stock fell nearly 30%, closing at $4.77 per share [8] Next Steps - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact the law firm Bragar Eagel & Squire, P.C. for more information [4][5]

Core Viewpoint - A class action lawsuit has been filed against KinderCare Learning Companies, Inc. for allegedly misleading investors regarding the quality of care provided at its facilities and undisclosed risks associated with child abuse incidents [3][4]. Company Overview - KinderCare Learning Companies, Inc. (NYSE: KLC) is facing legal action in the United States District Court District of Oregon on behalf of investors who purchased its IPOs [1]. - The lawsuit claims that the registration statement for the IPO was false and/or misleading, failing to disclose significant issues related to child care quality and safety [3]. Allegations - The lawsuit alleges that numerous incidents of child abuse, neglect, and harm occurred at KinderCare facilities [3]. - It is claimed that KinderCare did not provide the "highest quality care possible" and failed to meet basic standards in the child care industry [3]. - The company is accused of being exposed to material risks, including lawsuits, regulatory actions, and reputational damage due to these undisclosed issues [3]. Stock Performance - Since the IPO, KinderCare's stock price has fallen to lows near $9 per share, indicating a significant decline in investor confidence [4].

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and revenue outlook of its gene therapy ELEVIDYS, which is intended to treat Duchenne muscular dystrophy [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities that purchased Sarepta securities between June 22, 2023, and June 24, 2025 [1]. - Investors have until August 25, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations Against Sarepta - Sarepta is accused of making materially false and misleading statements about ELEVIDYS, leading investors to believe it was a safe therapy with a positive revenue outlook [3]. - Specific allegations include that ELEVIDYS posed significant safety risks, trial protocols failed to detect severe side effects, and adverse events would lead to recruitment halts and regulatory scrutiny [3]. Group 3: Stock Price Impact - Following a safety update on March 18, 2025, where a patient died after treatment, Sarepta's stock fell by $27.81 (27.44%) to close at $73.54 [4]. - After the announcement on April 4, 2025, regarding regulatory scrutiny, the stock dropped by $4.18 (7.13%) to close at $54.43 [4]. - A second patient death reported on June 15, 2025, led to a further decline of $15.24 (42.12%) to close at $20.91 [4]. - The FDA's Safety Communication on June 24, 2025, resulted in a stock price decrease of $1.52 (8.01%) to close at $17.46 [4].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding its business practices and partnerships, particularly concerning the promotion of Wegovy® and its collaboration with Novo Nordisk [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Hims securities between April 29, 2025, and June 23, 2025, with a deadline of August 25, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Hims engaged in deceptive practices by promoting illegitimate versions of Wegovy®, which posed risks to patient safety [3]. - It is claimed that the company's positive statements about its business and prospects were materially misleading due to undisclosed risks regarding its collaboration with Novo Nordisk [3][4]. Group 2: Allegations Against Hims - The complaint specifies that Hims failed to disclose that its communication with Novo Nordisk was not as beneficial as portrayed, potentially jeopardizing the long-term collaboration for access to Wegovy [4]. - It is alleged that Hims misrepresented the approval of its compounded semaglutide products by Novo Nordisk, which could mislead investors about the company's product offerings [4]. - The lawsuit highlights that Hims made false statements regarding the availability of branded Wegovy alongside its compounded products, which could mislead users and investors about the company's market position [4].